In this episode of the WTR Small-Cap Spotlight, Water Tower Research’s Tim Gerdeman is joined by Dr. Chris Witowski, CEO of Psilera, and WTR Senior Analyst Robert Sassoon for an insightful discussion on the company’s pioneering work in neuroplastogen drug development and delivery technologies.

Dr. Chris Witowski, CEO and Co-Founder of Psilera, an early-stage biotech company focused on developing next-generation neuroplastegens for neurological and neuropsychiatric disorders, shares his thoughts and insights on the evolution of biomarkers in the neurosciences, the latest developments and trends in CNS-focused biomarkers and the potentially transformative impact they will have on the CNS treatment landscape.

Tune in to learn more about Psilera’s vision for the future of neurotherapeutics and how the company is working to transform the treatment landscape for CNS disorders.

On this week’s WTR Biotech Spotlight, we speak with Apimeds CEO Erik Emerson about the newly NYSE listed company and the development of Apitox, a purified honeybee venom, for knee osteoarthritis and multiple sclerosis. We discuss the therapeutic properties of bee venom and the clinical/regulatory plans to bring Apitox to the US market. Listen to learn more about Apimeds and its novel approach to treat inflammatory pain.

CEO of Zomedica (OTCQB: ZOMDF) Larry Heaton joins WTR's Tim Gerdeman and Robert Sassoon in this week's WTR Small-Cap Spotlight episode. Since 2021 Zomedica has expanded its suite of innovative offerings from one product to six. All are proprietary, highly differentiated either diagnostic or therapeutic devices, to help veterinarians not only improve the quality of care for pets, but also importantly to help improve the efficiency of how vets themselves operate to maximize the profitability of their practices. Heaton provides a concise overview of Zomedica’s products, explains how they differentiate themselves from what exists in the market today and the company’s growth opportunities.

Enlivex Therapeutics CEO Oren Hershkovitz, PhD joins us on this week’s WTR Biotech Spotlight to talk about how the company’s cell therapy, Allocetra, reprograms macrophages to treat inflammatory diseases. We dive into the recent Phase 1 data in knee osteoarthritis and what to expect from the randomized Phase 2 readout later this year, as well as the market opportunity. Listen to learn more about Enlivex Therapeutics and its off-the-shelf cell therapy platform.

Tim Gerdeman and Do Kim discuss President Trump’s executive order on lowering drug prices through Most-Favored-Nation reference pricing. They talk about the goal of the executive order and whether the government has the authority for price-setting in the pharmaceutical industry.

Tim Gerdeman and Do Kim discuss the current state of biotech, what brought us here, and how the rest of year may look for the group. They also review recent market-shaping events in the obesity space and progress of the Keytruda-busting PD-1/VEGF bispecifics.

On this week's episode of WTR Biotech Spotlight, Tim Gerdeman and Robert Sassoon sit down for a quick flashcast to review Robert's last three reports; Neuroscience, Alzheimer’s and Biogen IOC.

Founding CEO and President of Annovis Bio (NYSE: ANVS) Dr Maria Maccecchini joins WTR's Tim Gerdeman and Robert Sassoon in this week's WTR Biotech Spotlight episode. Annovis is a late clinical-stage drug platform company developing novel disease-modifying therapies for neurodegenerative diseases, to include targeting Alzheimer's and Parkinson's, as well as other related diseases. Dr Maccecchini discusses the company's lead drug candidate Buntanetap and its promise as a treatment that can go beyond simply slowing the rate of cognitive decline in Alzheimer's and Parkinson's patients.